Close Menu

NEW YORK (GenomeWeb) – Qiagen said on Tuesday that it has received CE-IVD marking for its Therascreen PITX2 RGQ PCR kit and launched the assay in Europe.

The new kit is a methylation assay intended to help predict the response of certain high-risk breast cancer patients to anthracycline-based chemotherapy. It runs on Qiagen's Rotor-Gene Q MDx real-time thermal cycler and can easily be adopted by customers already running Therascreen assays on the company's QIAsymphony automation platform.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.